Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Natural Product (NP) Details

General Information of the NP (ID: NP9320)
Name
Lithium
Synonyms
7439-93-2; Li; Lithium; litio; UNII-9FN79X2M3F; 9FN79X2M3F; CHEBI:30145; MFCD00134051; Litium; Lithium, metallic; Lithium, elemental; Lithium, 99+%, granular, dry; Lithium compounds; 3Li; HSDB 647; EINECS 231-102-5; UN1415; monolithium; Lithium standard solution, for AAS, 1 mg-ml Li in 2% HCl; Hydrure de lithium [French]; Lithium ribbon; Lithium rod; HSDB 549; Lithium granules; EINECS 231-484-3; UN1414; UN2805; Normothymin-E (TN); Epitope ID:114079; EC 231-102-5; Lithium, 99%, low sodium; Lithium, 99%, high sodium; CHEMBL2146126; DTXSID5036761; HSDB 6900; 7321AH; AKOS015833388; AKOS015902481; HSD6900000; Lithium wire, 3.2mm (0.125in) dia; Lithium [UN1415] [Dangerous when wet]; Lithium granules, 1-6mm (0.04-0.2in); Lithium, granular, 99% trace metals basis; FT-0627905; C15473; D08133; EC 231-484-3; Lithium hydride [UN1414] [Dangerous when wet]; Lithium, shot, 99%, 4-16 mesh, in mineral oil; Lithium, wire, diam. 3.2 mm, in mineral oil, >=98%; Lithium, ~25 wt % dispersion in mineral oil, high sodium; Lithium, AAS standard solution, Specpure?, Li 1000?g/ml; Lithium, ingot, diam. 5.7 cm, 99.9% trace metals basis; Lithium, rod, diam. 12.7 mm, 99.9% trace metals basis; Lithium foil, 0.75mm (0.03in) thick x 19mm (0.75in) wide; Lithium hydride, fused solid [UN2805] [Dangerous when wet]; Lithium ingot, 5.7cm (2.2in) dia x 8.6cm (3.4in) long; Lithium, Oil based standard solution, Specpure, Li 5000g/g; Lithium, plasma standard solution, Specpure?, Li 10,000?g/ml; Lithium, plasma standard solution, Specpure?, Li 1000?g/ml; Lithium, rod, 12.7 mm diameter, length 165 mm, purity 99%; Lithium, rod, 12.7 mm diameter, length 200 mm, purity 99%; Lithium, foil, 25x100mm, thickness 0.6mm, as rolled, 99.9%; Lithium, Oil based standard solution, Specpure(R), Li 1000?g/g; Lithium, foil, thickness 0.6 mm, size 25 x 300 mm, purity 99.9%; Lithium, Ion chromatography standard solution, Specpure, Li+ 1000?g/ml; Lithium, wire (in mineral oil), diam. 3.2 mm, 99.9% trace metals basis; Lithium, foil, not light tested, 38x200mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 38x500mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 45x200mm, thickness 0.12mm, as rolled, 99.9%; Lithium, granular, 4-10 mesh particle size, high sodium, 99% (metals basis); Lithium, ribbon, thickness x W 0.38 mm x 23 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 19 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 45 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 1.5 mm x 100 mm, 99.9% trace metals basis
    Click to Show/Hide
Disease Fragile X chromosome [ICD-11: LD55] Phase 2 [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
Li
PubChem CID
3028194
Canonical SMILES
[Li]
InChI
1S/Li
InChIKey
WHXSMMKQMYFTQS-UHFFFAOYSA-N
CAS Number
CAS 7439-93-2
ChEBI ID
CHEBI:30145
Herb ID
HBIN033404
TTD Drug ID
D5MF8Y
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Pyrroloquinoline quinone      Osteoporosis     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation
Down-regulation Expression p38 beta  Molecule Info 
Pathway MAP
                    In-vivo Model Male APP/PS1 transgenic mice and littermate wild type control were used in this study.
                    Experimental
                    Result(s)
This study demonstrated the efficacy of a novel AD therapeutic strategy targeting at multiple disease-causing mechanisms through the synergistic effects of microdose lithium and pyrroloquinoline quinone.
Target and Pathway
Target(s) Glycogen synthase kinase-3 alpha (GSK-3A)  Molecule Info  [3]
Glycogen synthase kinase-3 beta (GSK-3B)  Molecule Info  [3]
KEGG Pathway ErbB signaling pathway Click to Show/Hide
2 Chemokine signaling pathway
3 Cell cycle
4 PI3K-Akt signaling pathway
5 Wnt signaling pathway
6 Hedgehog signaling pathway
7 Axon guidance
8 Hippo signaling pathway
9 Focal adhesion
10 Signaling pathways regulating pluripotency of stem cells
11 T cell receptor signaling pathway
12 B cell receptor signaling pathway
13 Neurotrophin signaling pathway
14 Dopaminergic synapse
15 Insulin signaling pathway
16 Melanogenesis
17 Prolactin signaling pathway
18 Thyroid hormone signaling pathway
19 Non-alcoholic fatty liver disease (NAFLD)
20 Alzheimer's disease
21 Hepatitis C
22 Measles
23 Influenza A
24 HTLV-I infection
25 Epstein-Barr virus infection
26 Pathways in cancer
27 Colorectal cancer
28 Endometrial cancer
29 Prostate cancer
30 Basal cell carcinoma
NetPath Pathway TGF_beta_Receptor Signaling Pathway Click to Show/Hide
Panther Pathway Alzheimer disease-presenilin pathway Click to Show/Hide
2 Angiogenesis
3 Cadherin signaling pathway
4 Hedgehog signaling pathway
5 Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
6 Insulin/IGF pathway-protein kinase B signaling cascade
7 Interleukin signaling pathway
8 PDGF signaling pathway
9 PI3 kinase pathway
10 Wnt signaling pathway
11 Ras Pathway
12 CCKR signaling map ST
Pathway Interaction Database LPA receptor mediated events Click to Show/Hide
2 Degradation of beta catenin
3 Reelin signaling pathway
4 Presenilin action in Notch and Wnt signaling
5 Integrin-linked kinase signaling
6 CDC42 signaling events
7 LKB1 signaling events
8 Canonical Wnt signaling pathway
9 Role of Calcineurin-dependent NFAT signaling in lymphocytes
10 Glucocorticoid receptor regulatory network
11 C-MYC pathway
12 Regulation of Androgen receptor activity
13 BMP receptor signaling
14 Hedgehog signaling events mediated by Gli proteins
15 Signaling events mediated by Stem cell factor receptor (c-Kit)
16 Validated transcriptional targets of deltaNp63 isoforms
17 Aurora A signaling
18 Insulin-mediated glucose transport
19 Class I PI3K signaling events mediated by Akt
20 p53 pathway
21 Trk receptor signaling mediated by PI3K and PLC-gamma
22 FOXM1 transcription factor network
Reactome Degradation of beta-catenin by the destruction complex Click to Show/Hide
2 AKT phosphorylates targets in the cytosol
3 Regulation of HSF1-mediated heat shock response
4 CRMPs in Sema3A signaling
5 Disassembly of the destruction complex and recruitment of AXIN to the membrane
6 S33 mutants of beta-catenin aren't phosphorylated
7 S37 mutants of beta-catenin aren't phosphorylated
8 S45 mutants of beta-catenin aren't phosphorylated
9 T41 mutants of beta-catenin aren't phosphorylated
10 Degradation of GLI2 by the proteasome
11 Constitutive Signaling by AKT1 E17K in Cancer
12 XBP1(S) activates chaperone genes
WikiPathways DNA Damage Response (only ATM dependent) Click to Show/Hide
2 Senescence and Autophagy in Cancer
3 Notch Signaling Pathway
4 Glycogen Metabolism
5 Insulin Signaling
6 Wnt Signaling Pathway
7 Wnt Signaling Pathway and Pluripotency
8 IL-6 signaling pathway
9 Wnt Signaling Pathway Netpath
10 Copper homeostasis
11 Focal Adhesion
12 Hair Follicle Development: Induction (Part 1 of 3)
13 Cardiac Hypertrophic Response
14 Degradation of beta-catenin by the destruction complex
15 T-Cell Receptor and Co-stimulatory Signaling
16 Cardiac Progenitor Differentiation
17 BDNF signaling pathway
18 Corticotropin-releasing hormone
19 B Cell Receptor Signaling Pathway
20 IL17 signaling pathway
21 Neural Crest Differentiation
22 Alzheimers Disease
23 IL-7 Signaling Pathway
24 Regulation of Microtubule Cytoskeleton
25 TWEAK Signaling Pathway
26 Leptin signaling pathway
27 Semaphorin interactions
28 Cell Cycle
29 MicroRNAs in cardiomyocyte hypertrophy
30 Androgen receptor signaling pathway
31 IL-5 Signaling Pathway
References
Reference 1 Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr. 2008 Aug;29(4):293-302.
Reference 2 Beneficial synergistic effects of microdose lithium with pyrroloquinoline quinone in an Alzheimer's disease mouse model. Neurobiol Aging. 2014 Dec;35(12):2736-2745.
Reference 3 The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874.
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China